Vical (NASDAQ:VICL) Upgraded to Buy by Zacks Investment Research

Share on StockTwits

Vical (NASDAQ:VICL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage currently has a $0.75 price target on the biotechnology company’s stock.

According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “

Vical stock traded up $0.03 during mid-day trading on Friday, hitting $0.75. The stock had a trading volume of 39,779 shares, compared to its average volume of 113,391. The firm’s 50-day moving average is $0.86. The firm has a market cap of $17.15 million, a PE ratio of -0.93 and a beta of 0.28. Vical has a 12 month low of $0.72 and a 12 month high of $1.47.

Vical (NASDAQ:VICL) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Vical had a negative net margin of 1,002.10% and a negative return on equity of 29.46%. Research analysts expect that Vical will post -0.36 earnings per share for the current year.

An institutional investor recently bought a new position in Vical stock. Virtu Financial LLC bought a new stake in Vical Incorporated (NASDAQ:VICL) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 121,693 shares of the biotechnology company’s stock, valued at approximately $146,000. Virtu Financial LLC owned 0.56% of Vical at the end of the most recent quarter. 33.78% of the stock is owned by hedge funds and other institutional investors.

Vical Company Profile

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Recommended Story: What is a Swap?

Get a free copy of the Zacks research report on Vical (VICL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.